Fresenius Medical Care FME.DE · EUR
Health Care · Health Care Providers & Services · XETRA · 🇩🇪 Germany
DAX
40.97
-2.98%
Close of 9 Nov 2026, in EUR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Fresenius Medical Care
Its shares trade on XETRA under the ticker FME.DE. It has been listed since 2 October 1996. It is a member of the DAX. In the fiscal year to 31 December 2025, it reported revenue of €19.63bn and net income of €978.0m. At that date it held total assets of €31.00bn and shareholders' equity of €13.31bn.
Fresenius Medical Care AG & Co. KGaA engages in the provision of products and services for patients with chronic kidney failure. The company is headquartered in Bad Homburg Vor Der Hohe, Hessen. The firm provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD), as well as other healthcare services. The firm also develops and manufactures a wide variety of health care products, which includes dialysis and non-dialysis products. Its dialysis products include hemodialysis machines, peritoneal cyclers, dialyzers, peritoneal solutions and granulates, bloodlines, renal pharmaceuticals and systems for water treatment. Its non-dialysis products include acute cardiopulmonary and apheresis products. The firm supplies dialysis clinics it owns, operates or manages with a broad range of products, and sells dialysis products to other dialysis service providers.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Providers & Services
- Listed since
- 2 Oct 1996
- Employees
- 121,403
- Website
- freseniusmedicalcare.com ↗
Leadership
Pay as last reported
- Mr. Michael SenChairman of the Supervisory Board, since 2023€509,000
- Ms. Helen GizaChairman of the Management Board, Chief Executive Officer€4.4m
- Ms. Stefanie BallingVice Chairman of the Supervisory Board, Employee Representatives, since 2024€320,000
- Mr. Martin FischerChief Financial Officer, Member of the Management Board€2.5m
- Mr. Craig CordolaMember of the Management Board, Chief Executive Officer - Care Delivery€3.7m
- Dr. Joerg HaeringMember of the Management Board - Legal, Compliance, Human Resources and Labor Relations Director€1.4m
- Dr. Frank MadduxMember of the Management Board, Global Chief Medical Officer€2.8m
- Dr. Katarzyna Mazur-HofsaessMember of the Management Board, Chief Executive Officer - Care Enablement€3.3m
- Mr. Shervin KorangyIndependent Member of the Supervisory Board€245,000
- Dr. Marcus KuhnertIndependent Member of the Supervisory Board€297,000
- Mr. A. Gregory SorensenIndependent Member of the Supervisory Board€213,000
- Ms. Pascale WitzIndependent Member of the Supervisory Board€299,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 81
- Environment
- 70
- Social
- 86
- Governance
- 88
- Direct emissions (scope 1)
- 360,803 t
- Energy emissions (scope 2)
- 450,611 t
- Value chain emissions (scope 3)
- 2,993,388 t
- Women in the workforce
- 70%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Fresenius Medical Care AG is a global leader in the field of dialysis and renal care, with a strong market presence in over 120 countries. The company benefits from its extensive network of clinics and partnerships, allowing it to provide comprehensive and high-quality services to patients worldwide.
- The company's strong financial performance and profitability are key strengths, enabling it to invest in research and development, expand its operations, and attract top talent. Fresenius Medical Care AG's strong brand reputation and recognized expertise further contribute to its competitive advantage in the market.
Weaknesses
- Despite its global presence, Fresenius Medical Care AG may face challenges in certain regions due to regulatory and reimbursement constraints. Adapting to diverse regulatory environments and addressing pricing pressures can potentially hinder the company's growth and profitability.
- As a specialized healthcare provider, Fresenius Medical Care AG's success heavily relies on the availability of skilled healthcare professionals, efficient supply chain management, and technological advancements. Any weaknesses in these areas may impact the company's ability to deliver consistent and high-quality care to its patients.
Opportunities
- The increasing incidence of chronic kidney diseases and the rising aging population present significant growth opportunities for Fresenius Medical Care AG. As the demand for renal care services continues to grow, the company can expand its market share by offering innovative treatment options and enhancing patient experience.
- Strategic collaborations and partnerships with healthcare providers, research institutions, and technology companies can also open up new avenues for Fresenius Medical Care AG to develop and deliver advanced dialysis solutions. Additionally, entering emerging markets with underserved renal care needs can fuel the company's expansion and revenue growth.
Threats
- Fresenius Medical Care AG operates in a highly competitive industry, facing competition from both established players and emerging entrants. Pricing pressures and the potential loss of key contracts can pose threats to the company's market position and profitability.
- Rapid advancements in medical technology and the potential disruption caused by new treatment methods or alternative therapies also present threats to the traditional dialysis market, requiring Fresenius Medical Care AG to adapt and innovate to stay ahead.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.